Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

Pharmapack Europe & CPHI have outlined key trends for pharma in 2025, highlighting the return of funding liquidity—via increased VC investments and PE capital for M&A—alongside enhanced supply chain ...

Pharma Sector Multibagger Opportunity - Explore how India could win big in the CDMO space with China-Plus-One strategy, ...

There is a significant discourse in the literature when estimating clinical trial costs due to the lack of transparency throughout the industry regarding the true expense of bringing a drug from bench ...